Cargando…

Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010

BACKGROUND: the most widely used tumor marker in ovarian cancer, often considered the ‘gold standard’ is CA125 but reliable clinical evidence demonstrates that human epididymis protein (HE4), used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasanbegovic, Lejla, Alicelebic, Selma, Sljivo, Nedeljka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AVICENA, d.o.o., Sarajevo 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430012/
https://www.ncbi.nlm.nih.gov/pubmed/26005273
http://dx.doi.org/10.5455/aim.2015.23.86-89
_version_ 1782371119286714368
author Hasanbegovic, Lejla
Alicelebic, Selma
Sljivo, Nedeljka
author_facet Hasanbegovic, Lejla
Alicelebic, Selma
Sljivo, Nedeljka
author_sort Hasanbegovic, Lejla
collection PubMed
description BACKGROUND: the most widely used tumor marker in ovarian cancer, often considered the ‘gold standard’ is CA125 but reliable clinical evidence demonstrates that human epididymis protein (HE4), used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease monitoring. AIM: to evaluate the reliability of the determination a tumor marker HE4 in comparison with CA125 on the Elecsys analyzer 2010 in epithelial ovarian cancer, benign ovarian cyst and healthy controls. METHODS: we prospectively determined CA125 and HE4 serum levels in the Biochemical-Immunological-Haematological “Medical Laboratory” Ilidza, Sarajevo, B&H between June 1(st) and December 31(st) 2011. Electro-chemiluminescence immunoassay (ECLIA) methods for quantitative determination in vitro were performed on the Roche/Hitachi Elecsys 2010 Immunoassay Analyzer. Standard methods of descriptive statistics were performed for the data analysis. RESULTS: univariate statistical analyze of tumor marker control serum revealed a high reliability for both CA125 and HE4 determination (p>0.05). Levey-Jennings charts of quality control data show that the target and the obtained values of both markers control sera do not differ significantly in relation to the ideal value. In a total number of 60 patients compared values of tumor markers show a high correlation (r=0.85). This study confirmed higher sensitivity and specificity of HE4 tumor marker compared with CA125. ROC-AUC values show that the diagnostic performance of HE4 was significantly higher compared with CA125. CONCLUSION: We concluded that HE4 was better than CA125 as a single tumor marker.
format Online
Article
Text
id pubmed-4430012
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AVICENA, d.o.o., Sarajevo
record_format MEDLINE/PubMed
spelling pubmed-44300122015-05-22 Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010 Hasanbegovic, Lejla Alicelebic, Selma Sljivo, Nedeljka Acta Inform Med Original Paper BACKGROUND: the most widely used tumor marker in ovarian cancer, often considered the ‘gold standard’ is CA125 but reliable clinical evidence demonstrates that human epididymis protein (HE4), used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease monitoring. AIM: to evaluate the reliability of the determination a tumor marker HE4 in comparison with CA125 on the Elecsys analyzer 2010 in epithelial ovarian cancer, benign ovarian cyst and healthy controls. METHODS: we prospectively determined CA125 and HE4 serum levels in the Biochemical-Immunological-Haematological “Medical Laboratory” Ilidza, Sarajevo, B&H between June 1(st) and December 31(st) 2011. Electro-chemiluminescence immunoassay (ECLIA) methods for quantitative determination in vitro were performed on the Roche/Hitachi Elecsys 2010 Immunoassay Analyzer. Standard methods of descriptive statistics were performed for the data analysis. RESULTS: univariate statistical analyze of tumor marker control serum revealed a high reliability for both CA125 and HE4 determination (p>0.05). Levey-Jennings charts of quality control data show that the target and the obtained values of both markers control sera do not differ significantly in relation to the ideal value. In a total number of 60 patients compared values of tumor markers show a high correlation (r=0.85). This study confirmed higher sensitivity and specificity of HE4 tumor marker compared with CA125. ROC-AUC values show that the diagnostic performance of HE4 was significantly higher compared with CA125. CONCLUSION: We concluded that HE4 was better than CA125 as a single tumor marker. AVICENA, d.o.o., Sarajevo 2015-04 2015-04-14 /pmc/articles/PMC4430012/ /pubmed/26005273 http://dx.doi.org/10.5455/aim.2015.23.86-89 Text en Copyright: © Lejla Hasanbegovic, Selma Alicelebic, Nedeljka Sljivo http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Hasanbegovic, Lejla
Alicelebic, Selma
Sljivo, Nedeljka
Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010
title Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010
title_full Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010
title_fullStr Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010
title_full_unstemmed Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010
title_short Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010
title_sort comparison of specific ovarian tumor markers by elecsys analyzer 2010
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430012/
https://www.ncbi.nlm.nih.gov/pubmed/26005273
http://dx.doi.org/10.5455/aim.2015.23.86-89
work_keys_str_mv AT hasanbegoviclejla comparisonofspecificovariantumormarkersbyelecsysanalyzer2010
AT alicelebicselma comparisonofspecificovariantumormarkersbyelecsysanalyzer2010
AT sljivonedeljka comparisonofspecificovariantumormarkersbyelecsysanalyzer2010